Brokerages Set LifeMD, Inc. (NASDAQ:LFMD) Price Target at $12.00

Shares of LifeMD, Inc. (NASDAQ:LFMD) have been given an average recommendation of “Buy” by the six analysts that are presently covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $12.00.

A number of analysts have recently issued reports on the company. Cantor Fitzgerald restated an “overweight” rating and issued a $15.00 target price on shares of LifeMD in a report on Friday, September 20th. B. Riley assumed coverage on LifeMD in a research note on Friday, August 23rd. They issued a “buy” rating and a $11.00 price objective for the company. Finally, KeyCorp lowered their target price on LifeMD from $12.00 to $10.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th.

LifeMD Stock Down 5.4 %

LFMD stock opened at $4.21 on Tuesday. The firm has a market cap of $175.80 million, a PE ratio of -5.69 and a beta of 1.18. LifeMD has a 12 month low of $4.10 and a 12 month high of $12.88. The company has a debt-to-equity ratio of 10.83, a current ratio of 0.87 and a quick ratio of 0.83. The firm has a 50 day simple moving average of $5.17 and a 200 day simple moving average of $7.38.

LifeMD (NASDAQ:LFMD) last issued its earnings results on Wednesday, August 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.06). The company had revenue of $50.66 million during the quarter, compared to analyst estimates of $48.47 million. During the same quarter last year, the firm earned ($0.23) EPS. Equities research analysts forecast that LifeMD will post -0.49 earnings per share for the current fiscal year.

Institutional Trading of LifeMD

Large investors have recently made changes to their positions in the stock. G2 Investment Partners Management LLC increased its position in LifeMD by 23.9% in the 4th quarter. G2 Investment Partners Management LLC now owns 688,050 shares of the company’s stock worth $5,704,000 after buying an additional 132,850 shares during the period. Vanguard Group Inc. grew its position in LifeMD by 12.5% during the 1st quarter. Vanguard Group Inc. now owns 1,155,193 shares of the company’s stock worth $11,875,000 after acquiring an additional 128,701 shares during the last quarter. Acadian Asset Management LLC increased its holdings in LifeMD by 261.8% during the 1st quarter. Acadian Asset Management LLC now owns 116,655 shares of the company’s stock valued at $1,198,000 after purchasing an additional 84,413 shares in the last quarter. Calamos Advisors LLC acquired a new stake in LifeMD during the 2nd quarter valued at $394,000. Finally, Virtu Financial LLC bought a new position in LifeMD in the 1st quarter valued at $249,000. Institutional investors own 35.52% of the company’s stock.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.